Base Editing Gene Therapy for Heterozygous Familial Hypercholesterolemia
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background
Heterozygous familial hypercholesterolemia (HeFH) is a genetic disorder characterized by persistently elevated low-density lipoprotein cholesterol (LDL-C) levels, leading to an increased risk of early-onset atherosclerosis cardiovascular diseases (ASCVD). YOLT-101, an in vivo base-editing therapeutic agent delivered via GalNAc-modified lipid nanoparticles, is designed to achieve permanent inactivation of proprotein convertase subtilisin/kexin type 9 ( PCSK9 ), enabling sustained LDL-C reduction.
Methods
This trial enrolled participants with heterozygous genetic mutations in the low-density lipoprotein receptor (LDLR), and LDL-C levels of ≥2.6 mmol/L (without ASCVD) or ≥1.8 mmol/L (with ASCVD) despite receiving moderate- or high-intensity statin therapy. Eligible patients received a single intravenous infusion of YOLT-101 at ascending doses (0.2, 0.4, and 0.6 mg/kg). We report interim results from an ongoing clinical trial evaluating the safety, tolerability, pharmacodynamics, and efficacy of YOLT-101.
Results
Six participants were enrolled (median age, 48 years, range, 34-62) in the study. The most common adverse events (AEs) were transient infusion-related reactions (83.3%) and elevations in alanine/aspartate aminotransferase (50%). No study withdrawals or AEs of grade 3 or higher occurred. PCSK9 and LDL-C levels decreased in a dose-dependent manner following YOLT-101 administration. In the 0.6mg/kg group (n=3), mean PCSK9 levels decreased by 55.9% at week 1 and by 75.8% and 72.5% after 1 and 4 months, respectively; corresponding LDL-C reductions were 33.2%, 48.9%, and 50.4%, respectively.
Conclusions
A single infusion of YOLT-101 at 0.6 mg/kg was well tolerated and led to sustained PCSK9 and LDL-C reduction, demonstrating promise for future clinical development. (Funded by YolTech Therapeutics; Registration Number: NCT06458010 )
